Characteristics of Population
| Characteristic | Control arm (n = 117, 49.6%) | Experimental arm (n = 119, 50.4%) |
|---|---|---|
| Median age (y) | 69.7 (51.5–81.2) | 69 (43.4–83.7) |
| Risk of patient | ||
| Intermediate | 41 (35%) | 46 (38.7%) |
| High | 76 (65%) | 73 (61.3%) |
| Familiarity | ||
| No | 74 (94.9%) | 52 (86.7%) |
| Yes | 4 (5.1%) | 8 (13.3%) |
| Missing data | 39 | 59 |
| Performance status* | ||
| <100 | 6 (5.7%) | 4 (3.8%) |
| =100 | 100 (94.3%) | 102 (96.2%) |
| Missing data | 11 | 13 |
| Initial PSA (ng/mL) | 8.36 (1.67–580) | 8.35 (2.40–98.31) |
| PSA category (ng/mL) | ||
| ≤4 | 9 (8.2%) | 10 (8.5%) |
| 4–10 | 56 (50.9%) | 57 (48.3%) |
| 10–20 | 30 (27.3%) | 30 (25.4%) |
| >20 | 15 (13.6%) | 21 (17.8%) |
| Gleason score | ||
| 6 | 1 (0.9%) | 4 (3.4%) |
| 7 | 49 (42.2%) | 53 (44.5%) |
| 8 | 51 (44%) | 42 (35.3%) |
| 9 | 13 (11.2%) | 15 (12.6%) |
| 10 | 2 (1.7%) | 5 (4.2%) |
| Missing data | 1 | |
| Clinical T stage | ||
| T1a-c | 13 (11.4%) | 18 (15.9%) |
| T2a-c | 87 (76.3%) | 80 (70.8%) |
| T3a-c | 14 (12.3%) | 15 (13.3%) |
| Missing data | 3 | 6 |
↵* Karnofsky performance status.
Qualitative data are number and percentage; continuous data are median and range.